Canada markets close in 2 hours 43 minutes

Minerva Neurosciences, Inc. (NERV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4800-0.0400 (-1.59%)
As of 11:48AM EDT. Market open.

Minerva Neurosciences, Inc.

1500 District Avenue
Burlington, MA 01803
United States
617 600 7373
https://www.minervaneurosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9

Key Executives

NameTitlePayExercisedYear Born
Dr. Remy Luthringer Ph.D.Executive Chairman & CEO1.27MN/A1961
Mr. Geoffrey Robin Race F.C.M.A., M.B.A.President913.3kN/A1961
Mr. Joseph ReillySenior VP & COO461kN/A1975
Mr. William B. BoniVice President of Investor Relations & Corporate CommunicationsN/AN/A1952
Prof. Michael Davidson M.D.Chief Medical Officer657.47kN/A1950
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Corporate Governance

Minerva Neurosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.